Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List
03 Maggio 2024 - 1:00PM
Orchard Therapeutics, recently acquired by Kyowa Kirin with the
goal of accelerating the delivery of new gene therapies to patients
around the globe, today announced that Bobby Gaspar, M.D., Ph.D.,
co-founder and chief executive officer, has been named to the
inaugural 2024 TIME100 Health, an annual list recognizing the
impact, innovation, and achievement of the world’s most influential
individuals in health this year. The full list and related tributes
will appear in the May 13, 2024 issue of TIME and is available
online at https://time.com/collection/time100-health/.
“I am incredibly humbled, privileged, and
immensely proud to be included on this esteemed list of influential
and accomplished people shaping the future of health care,” said
Dr. Gaspar. “While these accolades are often attributed to
individuals, I truly believe this honor extends to the entire team
at Orchard Therapeutics and our global network of clinical and
academic collaborators. It is because of your collective efforts
that we are transforming the treatment landscape for previously
intractable diseases, and I share this recognition with all of
you.”
Dr. Gaspar is a world-renowned physician and
scientist, as well as an accomplished executive with more than 30
years of experience in medicine and biotechnology. He has been a
pioneer in the evolution of hematopoietic stem cell (HSC) gene
therapy—bringing it from some of the first studies in patients into
late-stage clinical trials, and ultimately through Orchard’s first
regulatory approvals in Europe and the U.S., enabling the delivery
of these potentially transformative medicines to eligible children.
His unparalleled expertise and deep relationships with key
physicians and treatment centers around the world are integral to
Orchard’s efforts to identify patients with severe genetic diseases
through targeted disease education, early diagnosis and
comprehensive newborn screening. Dr. Gaspar is an honorary
professor of pediatrics and immunology at the University College
London (UCL) Great Ormond Street Institute of Child Health. He
studied medicine and surgery at Kings College in London before
completing his Ph.D. at the UCL Great Ormond Street Institute of
Child Health.
“Bobby is a visionary and authentic leader who
inspires the very best in his colleagues and peers,” said Frank
Thomas, president and chief operating officer of Orchard
Therapeutics. “He is a tremendous ambassador for the entire field
of HSC gene therapy, and I am thrilled his indelible contributions
to the advancement of human health are being recognized though his
inclusion on this prestigious list. Throughout his career, Bobby
has demonstrated an unwavering commitment to patient care—first as
a physician treating children with devastating genetic diseases,
then as a clinical academic who led multiple trials that have shown
HSC gene therapy can successfully correct the underlying cause of
these conditions, and now as a pioneering executive working to
unlock the full potential of this approach to deliver life-changing
therapies to patients in need. I am fortunate to call Bobby my
friend and business partner and appreciate the editors of TIME for
bestowing him with this well-deserved honor.”
“Bobby and I have a personal and professional
relationship spanning decades, and I am delighted to see this
acknowledgement of his accomplishments from a venerable mainstream
media institution,” said Donald Kohn, M.D., distinguished professor
of Microbiology, Immunology, Molecular Genetics and Pediatrics at
the University of California, Los Angeles (UCLA), member of the
UCLA Broad Stem Cell Research Center, and director of the UCLA
Human Gene and Cell Therapy Program. “Bobby boldly left a
fulfilling career in academia to translate the scientific
breakthroughs we were originating in our labs into
paradigm-shifting medicines that can be delivered at scale. This
was an audacious endeavor and success was anything but certain;
however, it is because of Bobby’s leadership that companies like
Orchard Therapeutics have made significant strides turning that
vision into reality. Congratulations, Bobby, and thank you for
helping carry the mantel for the broader HSC gene therapy
field.”
About Orchard
TherapeuticsOrchard Therapeutics, a Kyowa Kirin company,
is a global gene therapy leader focused on ending the devastation
caused by genetic and other severe diseases by discovering,
developing, and commercializing new treatments that tap into the
curative potential of hematopoietic stem cell (HSC) gene therapy.
In this approach, a patient’s own blood stem cells are genetically
modified outside of the body and then reinserted, with the goal of
correcting the underlying cause of disease with a single
treatment.
Founded in 2015, Orchard’s roots go back to some
of the first research and clinical developments involving HSC gene
therapy. Our team has played a central role in the evolution of
this technology from a promising scientific idea to a potentially
life-transforming reality. Today, Orchard is advancing a pipeline
of HSC gene therapies designed to address serious diseases where
the burden is immense for patients, families and society and
current treatment options are limited or do not exist.
For more information, please
visit www.orchard-tx.com.
About Kyowa KirinKyowa Kirin
aims to discover novel medicines with life-changing value. As a
Japan-based Global Specialty Pharmaceutical Company, we have
invested in drug discovery and biotechnology innovation for more
than 70 years and are currently working to engineer the next
generation of antibodies and cell and gene therapies with
the potential to help patients affected by a severe or
rare disease. A shared commitment to our values, to sustainable
growth, and to making people smile unites us across our four
regions – Japan, Asia Pacific, North America, and
EMEA/International. You can learn more about the business of Kyowa
Kirin at www.kyowakirin.com.
Contact
Benjamin Navon+1
857-248-9454Benjamin.Navon@orchard-tx.com
Grafico Azioni Orchard Therapeutics (NASDAQ:ORTX)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Orchard Therapeutics (NASDAQ:ORTX)
Storico
Da Giu 2023 a Giu 2024